Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?
Acute myeloid leukemia
Elderly
Fms-like tyrosine kinase 3 (FLT3) mutation
Hypomethylating
Nucleophosmin 1 (NPM1) mutation
PETHEMA
Treatment
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
17 Jun 2024
17 Jun 2024
Historique:
received:
15
03
2024
accepted:
08
06
2024
medline:
17
6
2024
pubmed:
17
6
2024
entrez:
17
6
2024
Statut:
aheadofprint
Résumé
FLT3-ITD and NPM1 mutations are key to defining the genetic risk profile of acute myeloid leukemia (AML). We aimed to assess the prognostic features of the FLT3-ITD and NPM1 mutations in old and/or unfit individuals with AML treated with non-intensive therapies in the era before azacitidine-venetoclax approbation. The results of various non-intensive regimens were also compared. We conducted a retrospective analysis that included patients treated with different non-intensive regimens, between 2007 and 2020 from PETHEMA AML registry. We compiled 707 patients with a median age of 74 years and median follow-up time of 37.7 months. FLT3-ITD patients (N = 98) showed a non-significant difference in overall survival (OS) compared to FLT3-ITD negative-patients (N = 608) (P = 0.17, median OS was 5 vs 7.3 months respectively). NPM1-mutated patients (N = 144) also showed a non-significant difference with NPM1 wild type (N = 519) patients (P = 0.25, median OS 7.2 vs 6.8 respectively). In the Cox regression analysis neither NPM1 nor FLT3-ITD nor age were significant prognostic variables for OS prediction. Abnormal karyotype and a high leukocyte count showed a statistically significant deleterious effect. Azacitidine also showed better survival compared to FLUGA (low dose cytarabine plus fludarabine). NPM1 and FLT3-ITD seem to lack prognostic value in older/unfit AML patients treated with non-intensive regimens other than azacitidine-venetoclax combination.
Identifiants
pubmed: 38884787
doi: 10.1007/s00277-024-05840-7
pii: 10.1007/s00277-024-05840-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Shimony S, Stahl M, Stone RM (2023) Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 98(3):502–526. https://doi.org/10.1002/ajh.26822
doi: 10.1002/ajh.26822
pubmed: 36594187
Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND et al (2016) Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374(23):2209–2221
doi: 10.1056/NEJMoa1516192
pubmed: 27276561
pmcid: 4979995
Yang JJ, Park TS, Wan TS (2017) Recurrent cytogenetic abnormalities in acute myeloid leukemia. Methods Mol Biol 1541:223–245
doi: 10.1007/978-1-4939-6703-2_19
pubmed: 27910027
Döhner H, Weisdorf DJ, Bloomfield CD (2015) Acute myeloid leukemia. N Engl J Med 373(12):1136–1152
doi: 10.1056/NEJMra1406184
pubmed: 26376137
Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345–1377. https://doi.org/10.1182/blood.2022016867
doi: 10.1182/blood.2022016867
pubmed: 35797463
Falini B, Brunetti L, Martelli MP (2021) How I diagnose and treat NPM1-mutated AML. Blood 137(5):589–599
doi: 10.1182/blood.2020008211
pubmed: 33171486
Bullinger L, Döhner K, Döhner H (2017) Genomics of Acute Myeloid Leukemia Diagnosis and Pathways. J Clin Oncol 35(9):934–946. https://doi.org/10.1200/JCO.2016.71.2208
doi: 10.1200/JCO.2016.71.2208
pubmed: 28297624
Sargas C, Ayala R, Larráyoz MJ, Chillón MC, Rodriguez-Arboli E, Bilbao C et al (2023) Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group. Blood Cancer J 13(1):77. https://doi.org/10.1038/s41408-023-00835-5
doi: 10.1038/s41408-023-00835-5
pubmed: 37173322
pmcid: 10182047
DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH et al (2020) Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med 383(7):617–629. https://doi.org/10.1056/NEJMoa2012971
doi: 10.1056/NEJMoa2012971
pubmed: 32786187
Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH et al (2015) International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 126(3):291–299. https://doi.org/10.1182/blood-2015-01-621664
doi: 10.1182/blood-2015-01-621664
pubmed: 25987659
pmcid: 4504945
Vives S, Martínez-Cuadrón D, Bergua Burgues J, Algarra L, Tormo M, Martínez-Sánchez MP; PETHEMA Group et al (2021) A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia. Cancer 127(12):2003–2014. https://doi.org/10.1002/cncr.33403
DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S et al (2020) Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135(11):791–803. https://doi.org/10.1182/blood.2019003988
doi: 10.1182/blood.2019003988
pubmed: 31932844
pmcid: 7068032
Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U et al (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99(12):4326–4335. https://doi.org/10.1182/blood.v99.12.4326
doi: 10.1182/blood.v99.12.4326
pubmed: 12036858
Kuendgen A, Müller-Thomas C, Lauseker M, Haferlach T, Urbaniak P, Schroeder T et al (2018) Efficacy of azacitidine is independent of molecular and clinical characteristics – an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature. Oncotarget 9(45):27882–27894. https://doi.org/10.18632/oncotarget.25328
doi: 10.18632/oncotarget.25328
pubmed: 29963245
pmcid: 6021252
Juliusson G, Jädersten M, Deneberg S, Lehmann S, Möllgård L, Wennström L et al (2020) The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting. Blood Adv 4(6):1094–1101
doi: 10.1182/bloodadvances.2019001335
pubmed: 32203582
pmcid: 7094014
Straube J, Ling VY, Hill GR, Lane SW (2018) The impact of age, NPM1
doi: 10.1182/blood-2017-09-807438
pubmed: 29183886
Ostronoff F, Othus M, Lazenby M, Estey E, Appelbaum FR, Evans A et al (2015) Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report. J Clin Oncol 33(10):1157–1164. https://doi.org/10.1200/JCO.2014.58.0571
doi: 10.1200/JCO.2014.58.0571
pubmed: 25713434
pmcid: 4372852
Sargas C, Ayala R, Larráyoz MJ, Chillón MC, Rodriguez-Arboli E; PETHEMA cooperative study group et al (2023) Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group. Blood Cancer J 13(1):77. https://doi.org/10.1038/s41408-023-00835-5 .
Ayala R, Carreño-Tarragona G, Barragán E, Boluda B, Larráyoz MJ et al (2022) Impact of FLT3-ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study. Cancers (Basel) 14(23):5799. https://doi.org/10.3390/cancers14235799
doi: 10.3390/cancers14235799
pubmed: 36497281
Labrador J, Martínez-Cuadrón D, de la Fuente A, Rodríguez-Veiga R, Serrano J, Tormo M et al (2022) Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry. Cancers (Basel) 14(9):2342. https://doi.org/10.3390/cancers14092342
doi: 10.3390/cancers14092342
pubmed: 35565471
DiGennaro J, Sallman DA (2023) TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines. Therapies and Future Considerations Acta Haematol. https://doi.org/10.1159/000535628
doi: 10.1159/000535628
pubmed: 38052186